Drug intelligence / Profile preview

ifosfamide + vinorelbine + filgrastim

Development stage: Unknown
Lead developer: Children's Oncology Group
Modality: Recombinant Proteins and Enzymes, Small Molecules
Administration: Intravenous, Subcutaneous

Overview

A combination chemotherapy regimen consisting of ifosfamide, vinorelbine, and filgrastim (G-CSF). This regimen has been studied primarily for relapsed/refractory Hodgkin Lymphoma and non-small-cell lung cancer. The treatment typically involves ifosfamide administered intravenously on days 1-4, vinorelbine administered intravenously on days 1 and 5, and filgrastim support beginning on day 6. For Hodgkin Lymphoma, it has been used as a re-induction therapy prior to stem cell transplantation.

Other names: IV regimenIV therapy

Targets

TUBB (Tubulin (alpha and beta subunits))CSF3R (Granulocyte colony-stimulating factor receptor)DNA

Beyond the preview

Go deeper on ifosfamide + vinorelbine + filgrastim.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ifosfamide + vinorelbine + filgrastim.

Explore the full profile